RenovoRx (RNXT) Chief Medical Officer adds 10,000 shares in open market buy

Rhea-AI Filing Summary

RenovoRx, Inc. Chief Medical Officer and director Ramtin Agah reported an open market purchase of the company’s common stock. On January 21, 2026, he bought 10,000 shares of RenovoRx common stock in open market transactions at a weighted average price of $0.9975 per share. The filing notes that the shares were acquired in multiple trades at prices ranging from $0.995 to $1.00 per share. Following this purchase, Agah directly holds 798,460 shares of RenovoRx common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Agah Ramtin

(Last) (First) (Middle)

C/O RENOVORX, INC.

2570 W EL CAMINO REAL, SUITE 320

(Street)

MOUNTAIN VIEW CA 94040

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RenovoRx, Inc. [ RNXT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		P		10,000(1)	A	$0.9975(2)	798,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects open market purchases of the Issuer's securities.

2. Reflects a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $0.995 to $1.00.

	/s/ Ramtin Agah	01/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RenovoRx (RNXT) report for Ramtin Agah?

RenovoRx (RNXT) reported that Chief Medical Officer and director Ramtin Agah purchased 10,000 shares of the company’s common stock in an open market transaction on January 21, 2026.

At what price did Ramtin Agah buy RenovoRx (RNXT) shares?

The filing states a weighted average purchase price of $0.9975 per share, with individual trades executed at prices ranging from $0.995 to $1.00 per share.

How many RenovoRx (RNXT) shares does Ramtin Agah own after this transaction?

After the reported purchase, Ramtin Agah beneficially owns 798,460 shares of RenovoRx common stock, held in direct ownership according to the filing.

Was the RenovoRx (RNXT) insider transaction an open market trade?

Yes. A footnote explains that the 10,000 shares were acquired through open market purchases of RenovoRx’s common stock.

What role does Ramtin Agah hold at RenovoRx (RNXT)?

According to the filing, Ramtin Agah is both a director of RenovoRx and its Chief Medical Officer.

Is the RenovoRx (RNXT) insider transaction held directly or indirectly?

The Form 4 identifies Ramtin Agah’s ownership of the 798,460 shares as direct (D), with no indirect ownership nature specified.